{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:03:50Z","timestamp":1789689830599,"version":"4.0.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","award":["PHRC-K 22\u2013182"],"award-info":[{"award-number":["PHRC-K 22\u2013182"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI radiopharm. chem."],"DOI":"10.1186\/s41181-026-00467-7","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:36:29Z","timestamp":1782228989000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fully GMP-complient radiosynthesis of [161Tb]Tb-PSMA-1 using the miniAiO synthesizer\u00a0for clinical translation"],"prefix":"10.1186","volume":"11","author":[{"given":"David","family":"Kryza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Le Fur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean No\u00ebl","family":"Badel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Morgat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fouzi","family":"Khayi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Giraudet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"467_CR1","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.3390\/cancers13092011","volume":"13","author":"P Bernhardt","year":"2021","unstructured":"Bernhardt P, Svensson J, Hemmingsson J, van der Meulen NP, Zeevaart JR, Konijnenberg MW, et al. Dosimetric analysis of terbium-161 for radionuclide therapy of metastatic prostate cancer. Cancers (Basel). 2021;13:2011. https:\/\/doi.org\/10.3390\/cancers13092011.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"467_CR2","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.2967\/jnumed.122.265039","volume":"64","author":"J Bolcaen","year":"2023","unstructured":"Bolcaen J, Gizawy MA, Terry SYA, Paulo A, Cornelissen B, Korde A, et al. Marshalling the potential of auger electron radiopharmaceutical therapy. J Nucl Med. 2023;64(9):1344\u201351. https:\/\/doi.org\/10.2967\/jnumed.122.265039.","journal-title":"J Nucl Med"},{"key":"467_CR3","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1470-2045(25)00332-8","volume":"26","author":"JP Buteau","year":"2025","unstructured":"Buteau JP, Kostos L, Jackson PA, Xie J, Haskali MB, Alipour R, et al. First-in-human results of terbium-161\u2013PSMA-I&T radioligand therapy in metastatic castration-resistant prostate cancer. Lancet Oncol. 2025;26:1009\u201317. https:\/\/doi.org\/10.1016\/S1470-2045(25)00332-8.","journal-title":"Lancet Oncol"},{"key":"467_CR4","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.3390\/molecules27134143","volume":"27","author":"V Di Iorio","year":"2022","unstructured":"Di Iorio V, Boschi S, Cuni C, Monti M, Severi S, Paganelli G, et al. Production and quality control of [177Lu]Lu-PSMA-I&T: development of an investigational medicinal product dossier for clinical trials. Molecules. 2022;27:4143. https:\/\/doi.org\/10.3390\/molecules27134143.","journal-title":"Molecules"},{"key":"467_CR5","unstructured":"European directorate for the quality of medicines & healthcare (EDQM). Lutetium (177Lu) zadavotide guraxetan injection. European Pharmacopoeia, 11th ed., Suppl. 11.7. Strasbourg; 2025."},{"key":"467_CR6","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00259-013-2374-2","volume":"40","author":"M Eder","year":"2013","unstructured":"Eder M, Eisenhut M, Babich J, Haberkorn U. PSMA as a target for radiolabelled small molecules. Eur J Nucl Med Mol Imaging. 2013;40:819\u201323. https:\/\/doi.org\/10.1007\/s00259-013-2374-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"467_CR7","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.2967\/jnumed.122.265268","volume":"64","author":"C Favaretto","year":"2023","unstructured":"Favaretto C, Grundler PV, Talip Z, Landolt S, Sepini L, K\u00f6ster U, et al. 161 Tb-DOTATOC production using a fully automated disposable cassette system: a first step toward the introduction of 161 Tb into the clinic. J Nucl Med. 2023;64:1138\u201344.","journal-title":"J Nucl Med"},{"key":"467_CR8","doi-asserted-by":"publisher","first-page":"759","DOI":"10.2967\/jnumed.115.170423","volume":"57","author":"E Hindi\u00e9","year":"2016","unstructured":"Hindi\u00e9 E, Zanotti-Fregonara P, Quinto MA, Morgat C, Champion C. Dose deposits from 90 Y, 177 Lu, 111 In, and 161 Tb in micrometastases of various sizes: implications for radiopharmaceutical therapy. J Nucl Med. 2016;57:759\u201364. https:\/\/doi.org\/10.2967\/jnumed.115.170423.","journal-title":"J Nucl Med"},{"key":"467_CR9","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3390\/cancers14061479","volume":"14","author":"MA Hoffmann","year":"2022","unstructured":"Hoffmann MA, von Eyben FE, Fischer N, Rosar F, M\u00fcller-H\u00fcbenthal J, Buchholz HG, et al. Comparison of [18F]PSMA-1007 with [68Ga]Ga-PSMA-11 PET\/CT in restaging of prostate cancer patients with PSA relapse. Cancers (Basel). 2022;14:1479. https:\/\/doi.org\/10.3390\/cancers14061479.","journal-title":"Cancers (Basel)"},{"key":"467_CR10","unstructured":"International Council for Harmonization. Impurities: guideline for residual solvents Q3C(R8). 2021."},{"key":"467_CR11","doi-asserted-by":"publisher","first-page":"260","DOI":"10.4103\/wjnm.WJNM_78_19","volume":"19","author":"E Jafari","year":"2020","unstructured":"Jafari E, Ahmadzadehfar H, Dadgar H, Assadi M. An overview on prostate-specific membrane antigen uptake in malignancies other than prostate cancer: a pictorial essay. World J Nucl Med. 2020;19:260\u20135.","journal-title":"World J Nucl Med"},{"issue":"1","key":"467_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s40336-025-00741-9","volume":"14","author":"Y Ji","year":"2026","unstructured":"Ji Y, Wang M, Yao Z, et al. The potential and research progress of 161Tb-based targeted radionuclide therapy. Clin Transl Imaging. 2026;14(1):3\u201310. https:\/\/doi.org\/10.1007\/s40336-025-00741-9.","journal-title":"Clin Transl Imaging"},{"key":"467_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27052290","volume":"27","author":"H Karimi","year":"2026","unstructured":"Karimi H, Shaffer TH, Stauff E, Kandula VVR, Kecskemethy HH, Averill LW, et al. Alpha and beta emitters in translational nuclear medicine: clinical advances, challenges, and future direction. Int J Mol Sci. 2026;27:2290. https:\/\/doi.org\/10.3390\/ijms27052290.","journal-title":"Int J Mol Sci"},{"key":"467_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s13139-025-00956-8","author":"J Ko","year":"2025","unstructured":"Ko J, et al. Automated synthesis of radiopharmaceuticals: technology, applications, and regulatory perspectives. Nucl Med Mol Imaging. 2025. https:\/\/doi.org\/10.1007\/s13139-025-00956-8.","journal-title":"Nucl Med Mol Imaging"},{"key":"467_CR15","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/pros.23522","volume":"78","author":"B Kranzb\u00fchler","year":"2018","unstructured":"Kranzb\u00fchler B, Salemi S, Umbricht C, M\u00fcller C, Burger I, Sulser T, et al. Pharmacological upregulation of prostate-specific membrane antigen expression in prostate cancer cells. Prostate. 2018;78:758\u201365.","journal-title":"Prostate"},{"issue":"1","key":"467_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11702-8","volume":"24","author":"D Kryza","year":"2024","unstructured":"Kryza D, Vinceneux A, Bidaux AS, Garin G, Tatu D, Cropet C, et al. A multicentric, single arm, open-label, phase I\/II study evaluating PSMA targeted radionuclide therapy in adult patients with metastatic clear cell renal cancer (PRadR). BMC Cancer. 2024;24(1):163. https:\/\/doi.org\/10.1186\/s12885-023-11702-8.","journal-title":"BMC Cancer"},{"key":"467_CR17","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2967\/jnumed.119.234187","volume":"61","author":"J Kuten","year":"2020","unstructured":"Kuten J, Fahoum I, Savin Z, Shamni O, Gitstein G, Hershkovitz D, et al. Head-to-Head Comparison of 68 Ga-PSMA-11 with 18 F-PSMA-1007 PET\/CT in staging prostate cancer using histopathology and immunohistochemical analysis as a reference standard. J Nucl Med. 2020;61:527\u201332. https:\/\/doi.org\/10.2967\/jnumed.119.234187.","journal-title":"J Nucl Med"},{"key":"467_CR18","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.3390\/pharmaceutics16121535","volume":"16","author":"A Larenkov","year":"2024","unstructured":"Larenkov A, Mitrofanov I, Rakhimov M. Improvement of radiochemical purity of [177Lu]Lu-DOTA-PSMA ligands. Pharmaceutics. 2024;16:1535. https:\/\/doi.org\/10.3390\/pharmaceutics16121535.","journal-title":"Pharmaceutics"},{"issue":"7","key":"467_CR19","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.7150\/thno.124671","volume":"16","author":"SY Lee","year":"2026","unstructured":"Lee SY, Manning HC. Contemporary opportunities and potential of Auger electron-emitting theranostics. Theranostics. 2026;16(7):3735\u201370. https:\/\/doi.org\/10.7150\/thno.124671.","journal-title":"Theranostics"},{"key":"467_CR20","doi-asserted-by":"publisher","first-page":"9755","DOI":"10.3390\/ijms25179755","volume":"25","author":"J Maes","year":"2024","unstructured":"Maes J, Gesqui\u00e8re S, De Spiegeleer A, Maes A, Van de Wiele C. Prostate-specific membrane antigen biology and pathophysiology in prostate carcinoma: implications for targeted imaging and therapy. Int J Mol Sci. 2024;25:9755. https:\/\/doi.org\/10.3390\/ijms25179755.","journal-title":"Int J Mol Sci"},{"key":"467_CR21","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.2967\/jnumed.124.267816","volume":"65","author":"V Murthy","year":"2024","unstructured":"Murthy V, Voter AF, Nguyen K, Allen-Auerbach M, Chen L, Caputo S, et al. Efficacy and toxicity of [177Lu]Lu-PSMA-617 for metastatic castration-resistant prostate cancer: results from the U.S. Expanded-access program and comparisons with phase 3 VISION Data. J Nucl Med. 2024;65:1740\u20134. https:\/\/doi.org\/10.2967\/jnumed.124.267816.","journal-title":"J Nucl Med"},{"key":"467_CR22","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.euf.2021.02.006","volume":"7","author":"JT Nauseef","year":"2021","unstructured":"Nauseef JT, Bander NH, Tagawa ST. Emerging prostate-specific membrane antigen-based therapeutics: small molecules, antibodies, and beyond. Eur Urol Focus. 2021;7:254\u20137. https:\/\/doi.org\/10.1016\/j.euf.2021.02.006.","journal-title":"Eur Urol Focus"},{"issue":"1","key":"467_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s41181-025-00335-w","volume":"10","author":"CM Ntihabose","year":"2025","unstructured":"Ntihabose CM, Handula M, Piet A, Beekman S, van Dalen L, Eskandari N, et al. Highlight selection of radiochemistry and radiopharmacy developments by editorial board. EJNMMI Radiopharm Chem. 2025;10(1):64. https:\/\/doi.org\/10.1186\/s41181-025-00335-w.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"467_CR24","first-page":"1902","volume":"36","author":"JA O\u2019Donoghue","year":"1995","unstructured":"O\u2019Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med. 1995;36:1902\u20139.","journal-title":"J Nucl Med"},{"key":"467_CR25","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"key":"467_CR26","doi-asserted-by":"crossref","unstructured":"Schulte ML, Rosenberg AJ. Automated manufacturing of carbon-11 radiopharmaceuticals using cassette-based radiosynthesizers. J Label Compd Radiopharm. 2025.","DOI":"10.1002\/jlcr.4166"},{"key":"467_CR27","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"145","key":"467_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2025.108998","volume":"144","author":"F Trejtnar","year":"2025","unstructured":"Trejtnar F, B\u00e1rta P, Kozempel J, Vlk M, \u010eurinov\u00e1 A, Kucha\u0159ov\u00e1 M, et al. Terbium-161 in nuclear medicine: preclinical and clinical progress in comparison with lutetium-177. Nucl Med Biol. 2025;144(145):108998. https:\/\/doi.org\/10.1016\/j.nucmedbio.2025.108998.","journal-title":"Nucl Med Biol"},{"key":"467_CR29","doi-asserted-by":"publisher","first-page":"6403","DOI":"10.1007\/s10967-024-09809-8","volume":"333","author":"E Uygur","year":"2024","unstructured":"Uygur E, Sezgin C, Parlak Y, et al. The radiolabeling of [161Tb]Tb-PSMA-617 by a novel radiolabeling method and preclinical evaluation by in vitro\/in vivo methods. J Radioanal Nucl Chem. 2024;333:6403\u201313. https:\/\/doi.org\/10.1007\/s10967-024-09809-8.","journal-title":"J Radioanal Nucl Chem"},{"key":"467_CR30","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.7150\/thno.92775","volume":"14","author":"K Van Laere","year":"2024","unstructured":"Van Laere K, Koole M, Deroose CM, De Voorde MV, Baete K, Cocolios TE, et al. Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside. Theranostics. 2024;14:1720\u201343. https:\/\/doi.org\/10.7150\/thno.92775.","journal-title":"Theranostics"},{"key":"467_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.811044","volume":"10","author":"L Wang","year":"2022","unstructured":"Wang L, Lu B, He M, Wang Y, Wang Z, Du L. Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019. Front Public Health. 2022;10:811044. https:\/\/doi.org\/10.3389\/fpubh.2022.811044.","journal-title":"Front Public Health"},{"key":"467_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117829","volume":"296","author":"L Wang","year":"2025","unstructured":"Wang L, Lu C, Wang X, Wu D. PSMA-targeted therapy: from molecular mechanisms to clinical breakthroughs in castration-resistant prostate cancer. Eur J Med Chem. 2025;296:117829. https:\/\/doi.org\/10.1016\/j.ejmech.2025.117829.","journal-title":"Eur J Med Chem"},{"key":"467_CR33","unstructured":"Xiao Y, Benedict S, Cui Y, Glide-Hurst C, Graves S, Jia X, et al. Embracing the future of clinical trials in radiotherapy: NRG Oncology CIRO technology retreat whitepaper. Int J Radiat Oncol Biol Phys. 2025."},{"key":"467_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1743628","volume":"15","author":"L Xiao","year":"2026","unstructured":"Xiao L, Zhao Z, Luo R, Liu F, Hu B, Zhao P, et al. 161Tb-PSMA radioligand therapy in prostate cancer: current evidence and future perspectives. Front Oncol. 2026a;15:1743628. https:\/\/doi.org\/10.3389\/fonc.2025.1743628.","journal-title":"Front Oncol"},{"key":"467_CR35","doi-asserted-by":"publisher","first-page":"1743628","DOI":"10.3389\/fonc.2025.1743628","volume":"15","author":"L Xiao","year":"2026","unstructured":"Xiao L, Zhao Z, Luo R, Liu F, Hu B, Zhao P, et al. 161Tb-PSMA radioligand therapy in prostate cancer: current evidence and future perspectives. Front Oncol. 2026b;15:1743628. https:\/\/doi.org\/10.3389\/fonc.2025.1743628.","journal-title":"Front Oncol"},{"issue":"3","key":"467_CR36","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s44197-023-00103-6","volume":"13","author":"W Zhang","year":"1990","unstructured":"Zhang W, Cao G, Wu F, Wang Y, Liu Z, Hu H, et al. Global burden of prostate cancer and association with socioeconomic status, 1990\u20132019: a systematic analysis from the global burden of disease study. J Epidemiol Global Health. 1990;13(3):407\u201321.","journal-title":"J Epidemiol Global Health"}],"container-title":["EJNMMI Radiopharmacy and Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41181-026-00467-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-026-00467-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-026-00467-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:11:04Z","timestamp":1789686664000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41181-026-00467-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["467"],"URL":"https:\/\/doi.org\/10.1186\/s41181-026-00467-7","relation":{},"ISSN":["2365-421X"],"issn-type":[{"value":"2365-421X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"27 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"69"}}